Reports Q3 revenue $90.95M, consensus $87.53M. "Accolade enters the new year having just concluded one of the strongest selling performances in our company’s history. Notably, the strength in our business is driven by the increasing diversity in our platform across solutions, customer types, distribution channels, and industry sectors. Accolade is leading the conversation with customers because of our proven track record of delivering measurable improvements in health and cost outcomes, and because our solutions are Engineered to Care," said Rajeev Singh, Accolade CEO.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ACCD:
- Accolade Announces Results for Fiscal Third Quarter 2023
- Accolade options imply 10.9% move in share price post-earnings
- Accolade Announces Participation in 25th Annual Needham Growth Conference
- Piper views TriCare T-5 contract awards as neutral for Accolade
- Accolade to Announce Fiscal Third Quarter 2023 Financial Results